MDGL
Neutral signalScored 2026-09-15 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Madrigal Pharmaceuticals, Inc.
- Nom
- Madrigal Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $10.0B
- Employés
- 915
- PDG
- William J. Sibold
- Site web
- https://www.madrigalpharma.com
- Marché
- ALTIVAMAZENAMSSGMTVKTX
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 11 583 titres (~6 141 631,42 $ US)
- Insiders
- Sibold William John
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$494,313
Avg sell (VWAP, 90d window) $523.64 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$152,373 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-11
- Last synced
-
2026-09-17 09:54:31
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-11 | Sibold William John | Sell · S · 10b5-1 | 120 | $546.38 | $65,565 | Form 4 |
| 2026-09-09 | Sibold William John | Sell · S · 10b5-1 | 160 | $542.55 | $86,808 | Form 4 |
| 2026-08-17 | Kelley Shannon T | Sell · S | 664 | $514.97 | $341,940 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | Sale | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-15 Drivers: fundamentals. Moteurs : fondamentaux.
MDGL shows meaningful operational progress with strong gross margins and Rezdiffra commercial traction, but the combination of a weak catalyst score (25/NONE) and a notable insider sale of ~$6.14M with zero buys creates…
The first sentence of the analysis written for MDGL on 2026-09-15 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.01 · operating margin -31% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 94.1% | 96.5% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -27.8% | -250.5% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -27.6% | -249.9% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -31.3% | -276.4% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -30.1% | -258.6% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 4.015 | 6.102 | 5.376 | 3.118 | 3.536 | |
| Quick Ratio | 3.774 | 5.901 | 5.376 | 3.118 | 3.536 | |
| Solvency Ratio | -0.437 | -1.615 | -1.586 | -1.785 | -3.126 | |
| Cash Ratio | 0.640 | 0.591 | 0.843 | 2.861 | 0.472 | |
| Price To Earnings Ratio | -45.318 | -14.090 | -11.575 | -16.846 | -5.792 | |
| Price To Earnings Growth Ratio | 1.097 | -1.475 | -0.723 | -0.948 | -0.492 | |
| Forward Price To Earnings Growth Ratio | 1.097 | -1.475 | -0.723 | -0.948 | -0.492 | |
| Price To Earnings Diluted Ratio | -45.318 | -14.090 | -11.575 | -16.846 | -5.792 | |
| Price To Earnings Diluted Growth Ratio | 1.097 | -1.475 | -0.723 | -0.948 | -0.492 | |
| Price To Book Ratio | 21.677 | 8.701 | 10.668 | 25.199 | 7.145 | |
| Price To Sales Ratio | 13.631 | 36.441 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -68.753 | -14.363 | -13.276 | -22.100 | -7.610 | |
| Price To Operating Cash Flow Ratio | -68.922 | -14.409 | -13.336 | -22.121 | -7.619 | |
| Debt To Assets Ratio | 0.281 | 0.115 | 0.183 | 0.138 | 0.003 | |
| Debt To Equity Ratio | 0.588 | 0.159 | 0.289 | 0.253 | 0.004 | |
| Debt To Capital Ratio | 0.370 | 0.137 | 0.224 | 0.202 | 0.004 | |
| Long Term Debt To Capital Ratio | 0.365 | 0.135 | 0.222 | 0.200 | 0.000 | |
| Financial Leverage Ratio | 2.090 | 1.382 | 1.580 | 1.837 | 1.394 | |
| Working Capital Turnover Ratio | 1.065 | 0.261 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -0.611 | -2.691 | -2.735 | -1.940 | -2.394 | |
| Operating Cash Flow Sales Ratio | -0.198 | -2.529 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.003 | 1.005 | 1.001 | 1.001 | |
| Debt Service Coverage Ratio | -11.337 | -30.681 | -28.350 | -73.390 | 0.000 | |
| Interest Coverage Ratio | -13.452 | -33.936 | -29.932 | -74.059 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -186.201 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.535 | -3.810 | -2.767 | -4.507 | -230.762 | |
| Capital Expenditure Coverage Ratio | -405.895 | -311.609 | -219.222 | -1,036.207 | -879.986 | |
| Dividend Paid And Capex Coverage Ratio | -405.895 | -311.609 | -219.222 | -1,036.207 | -879.986 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -49.987 | -14.626 | -12.046 | -16.130 | -5.657 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 94.1% | ▼-2.4% | ▲56.0% |
| Ebit Margin | -27.8% | ▲222.7% | ▲27.9% |
| Ebitda Margin | -27.6% | ▲222.3% | ▲27.9% |
| Operating Profit Margin | -31.3% | ▲245.1% | ▲30.2% |
| Pretax Profit Margin | -30.1% | ▲228.6% | ▲27.7% |
| Continuous Operations Profit Margin | -30.1% | ▲228.6% | ▲27.7% |
| Net Profit Margin | -30.1% | ▲228.6% | ▲27.7% |
| Bottom Line Profit Margin | -30.1% | ▲228.6% | ▲27.7% |
| Current Ratio | 4.015 | ▼-2.087 | ▼-0.414 |
| Quick Ratio | 3.774 | ▼-2.127 | ▼-0.567 |
| Solvency Ratio | -0.437 | ▲1.178 | ▲1.273 |
| Cash Ratio | 0.640 | ▲0.050 | ▼-0.441 |
| Price To Earnings Ratio | -45.318 | ▼-31.228 | ▼-26.594 |
| Price To Earnings Growth Ratio | 1.097 | ▲2.571 | ▲1.605 |
| Forward Price To Earnings Growth Ratio | 1.097 | ▲2.571 | ▲1.605 |
| Price To Earnings Diluted Ratio | -45.318 | ▼-31.228 | ▼-26.594 |
| Price To Earnings Diluted Growth Ratio | 1.097 | ▲2.571 | ▲1.605 |
| Price To Book Ratio | 21.677 | ▲12.975 | ▲6.999 |
| Price To Sales Ratio | 13.631 | ▼-22.809 | ▲3.617 |
| Price To Free Cash Flow Ratio | -68.753 | ▼-54.390 | ▼-43.533 |
| Price To Operating Cash Flow Ratio | -68.922 | ▼-54.513 | ▼-43.641 |
| Debt To Assets Ratio | 0.281 | ▲0.167 | ▲0.137 |
| Debt To Equity Ratio | 0.588 | ▲0.429 | ▲0.330 |
| Debt To Capital Ratio | 0.370 | ▲0.233 | ▲0.183 |
| Long Term Debt To Capital Ratio | 0.365 | ▲0.230 | ▲0.181 |
| Financial Leverage Ratio | 2.090 | ▲0.708 | ▲0.433 |
| Working Capital Turnover Ratio | 1.065 | ▲0.805 | ▲0.800 |
| Operating Cash Flow Ratio | -0.611 | ▲2.080 | ▲1.463 |
| Operating Cash Flow Sales Ratio | -0.198 | ▲2.331 | ▲0.348 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.001 | -0.000 |
| Debt Service Coverage Ratio | -11.338 | ▲19.344 | ▲17.414 |
| Interest Coverage Ratio | -13.452 | ▲20.484 | ▲16.824 |
| Short Term Operating Cash Flow Coverage Ratio | -186.201 | ▼-186.201 | ▼-148.961 |
| Operating Cash Flow Coverage Ratio | -0.535 | ▲3.275 | ▲47.941 |
| Capital Expenditure Coverage Ratio | -405.895 | ▼-94.286 | ▲164.689 |
| Dividend Paid And Capex Coverage Ratio | -405.895 | ▼-94.286 | ▲164.689 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -49.987 | ▼-35.361 | ▼-30.298 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $13.06B | $6.56B | $4.32B | $4.97B | $1.40B | |
| Enterprise value | $13.22B | $6.58B | $4.34B | $4.69B | $1.37B | |
| EV / Sales | 13.79x | 36.55x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -69.74x | -14.45x | -13.39x | -20.87x | -7.43x | |
| EV / Free cash flow | -69.57x | -14.40x | -13.33x | -20.85x | -7.42x | |
| EV / EBITDA | -49.99x | -14.63x | -12.05x | -16.13x | -5.66x | |
| Net debt / EBITDA | -0.59x | -0.04x | -0.05x | 0.97x | 0.15x | |
| Current ratio | 4.01x | 6.10x | 5.38x | 3.12x | 3.54x | |
| Income quality | 0.66x | 0.98x | 0.87x | 0.76x | 0.76x | |
| Graham net-net | $21 | $33 | $21 | $11 | $12 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 108.4% | 103.3% | 103.5% | 101.4% | 100.0% | |
| Working capital | $935.5M | $863.6M | $518.7M | $245.5M | $194.8M | |
| Invested capital | $949.3M | $873.0M | $522.0M | $246.7M | $196.5M | |
| Return on assets | -22.9% | -44.7% | -58.3% | -81.5% | -88.5% | |
| Operating ROA | -26.1% | -59.2% | -75.9% | -92.3% | -86.6% | |
| Return on tangible assets | -23.0% | -44.9% | -58.3% | -81.5% | -88.5% | |
| Return on equity | -47.8% | -61.8% | -92.2% | -149.6% | -123.3% | |
| Return on invested capital | -31.6% | -57.0% | -72.8% | -118.7% | -123.1% | |
| Return on capital employed | -31.6% | -57.0% | -72.9% | -119.0% | -123.4% | |
| Earnings yield | -2.2% | -7.1% | -8.6% | -5.9% | -17.3% | |
| Free cash flow yield | -1.5% | -7.0% | -7.5% | -4.5% | -13.1% | |
| Capex / Op. cash flow | -0.2% | -0.3% | -0.5% | -0.1% | -0.1% | |
| Capex / Depreciation | 9.9% | 210.1% | 280.6% | 46.5% | 51.6% | |
| Capex / Sales | 0.0% | 0.8% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 84.9% | 241.5% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 40.5% | 131.4% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 10.2% | 44.3% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.6% | 0.5% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 51d | 109d | 0d | 0d | 0d | |
| Days payables outstanding | 318d | 2553d | 0d | 0d | 0d | |
| Operating cycle | 538d | 2104d | 0d | 0d | 0d | |
| Cash conversion cycle | 220d | -449d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-16 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2026 and September 14, 2026 to a total of 27 new non-executive employees as equity inducement awards under the terms of Madrigal''s 2025 Inducement Plan. The equity awards were approved by Madrigal''s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-14 VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 1,800 Madrigal Pharmaceuticals, Inc. $MDGL VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,800 shares of the biopharmaceutical company''s stock, valued at approximately $967,000. A number of other large investors
- 2026-09-10 Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
- 2026-09-10 Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? Madrigal''s only commercial drug, Rezdiffra, continues to grow sales. Institutional investors hold more than 95% of the stock''s float.
- 2026-09-02 Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept.
- 2026-08-31 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Analysts Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eighteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fifteen have issued a buy rating on the
- 2026-08-25 Here''s Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off MASH cirrhosis could significantly expand Rezdiffra''s addressable market. Madrigal''s developing pipeline could reduce its dependence on Rezdiffra.
- 2026-08-22 Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL Allworth Financial LP bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 3,562 shares of the biopharmaceutical company''s stock, valued at approximately $1,913,000. Several other hedge funds and other institutional investors
- 2026-08-20 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal''s 2025 Inducement Plan. The equity awards were approved by Madrigal''s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-08-17 Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands Madrigal Pharmaceuticals (NASDAQ: MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts. Speaking at a Canaccord Genuity event, Chief Financial Officer Mardi Dier said the company reported $364 million in second-quarter revenue,